Related content

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

By Prebet Thomas   Charbonnier Aude   Gelsi-Boyer Véronique   Mozziconacci Marie Joelle   Blaise Didier   Vey Norbert  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1538-1540

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB

By              

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 355-359

Spandidos Publications

Access to resources Recommend Favorite

Erythroid but not cytogenetic response in a case with 5q− syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?

By Vigna Ernesto   Recchia Anna Grazia   Cuzzola Maria   Morabito Lucio   Gentile Massimo   Morabito Fortunato  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1408-1409

Informa Healthcare

Access to resources Recommend Favorite

Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy

By Smith B. Douglas   Mahmoud Dalia   Dacosta-Byfield Stacey   Rosen Virginia M.  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1119-1125

Informa Healthcare

Access to resources Recommend Favorite

Complications of 5azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome

By                

Oncology Letters, Vol. 6, Iss. 6, 2013-01 ,pp. : 1756-1758

Spandidos Publications

Access to resources Recommend Favorite